Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

C2174005

Cilazapril impurity D

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

(1S,9S)-9-{[(R)-1-Ethoxycarbonyl-3-phenylpropyl]amino}-10- oxo-octahydro-6H-pyridazino[1,2a][1,2]diazepine-1-carboxylic acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Sélectionner une taille de conditionnement

10 MG
107,00 €

107,00 €


Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit.

Devis pour commande en gros

Sélectionner une taille de conditionnement

Changer de vue
10 MG
107,00 €

About This Item

Formule empirique (notation de Hill) :
C22H31N3O5
Numéro CAS:
Poids moléculaire :
417.50
Numéro MDL:
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

107,00 €


Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit.

Devis pour commande en gros

Qualité

pharmaceutical primary standard

Famille d'API

cilazapril

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cilazapril impurity D EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

IgA nephropathy: a disease in search of a large-scale clinical trial to reliably inform practice.
Giovanni F M Strippoli et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 53(1), 5-8 (2008-12-23)
Leszek Tylicki et al.
Scandinavian journal of urology and nephrology, 42(4), 381-388 (2009-02-21)
Despite the proven effectiveness of combination therapy with an angiotensin I-converting enzyme inhibitor (ACEI) and angiotensin II-receptor blockers (ARBs) for the prevention and treatment of kidney disease, it has not proved possible to inhibit the progress of chronic nephropathies completely.
High-dose angiotensin-converting enzyme inhibitor attenuates oxidative stress in patients with chronic kidney disease.
Marcin Renke et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 24(2), 689-690 (2008-12-05)
Mustafa Tuncer et al.
Advances in therapy, 25(2), 99-105 (2008-02-26)
P-wave dispersion (PWD) has been shown to be a non-invasive electrocardiographic predictor for development of atrial fibrillation (AF). Thus, it may be possible to decrease AF risk through improvement in PWD. Our objective was to compare the effects of cilazapril
Yan-Xing Zhang et al.
Internal medicine (Tokyo, Japan), 47(9), 867-875 (2008-05-03)
Reversible posterior encephalopathy syndrome (RPES) is a clinical entity characterized with headache, nausea, vomiting, seizures, consciousness disturbance, and frequently visual disorders associated with neuroradiological findings, predominantly white matter abnormalities of the parieto-occipital lobes. The central nervous system manifestations of systemic

Questions

Reviews

No rating value

Active Filters

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique